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Abstract
Background: To assess the neuroprotective effect of etanercept (Enbrel®) which is a commercialized Tumor necrosis
factor-α (TNF-α) inhibitor on axonal injury in an animal model of acute ischemia.
Methods: Acute ischemia was induced by intraocular pressure elevation in 36 rats. The treatment groups underwent
subcutaneous injection of etanercept (0.3 or 1.0 mg/kg) three times per week up to 4 weeks. The control groups were
treated in the same manner using the same volume of phosphate-buffered saline (PBS). Optic nerve damage was
evaluated by counting the number of axons under a transmission electron microscope. Microglial cell activity was
assessed using Iba1 and CD68.
Results: After induction of ischemia, the ratio of preserved axons was significantly greater in the 2-week 1.
0-mg/kg etanercept-treated group than in the PBS-treated group (p = 0.062). The 4-week 0.3-mg/kg and 1.
0-mg/kg etanercept-treated groups also showed significantly higher ratios of preserved axons than did the
PBS-treated group (p = 0.021 and 0.003, respectively). The expression of Iba1 and CD68 in the optic nerve was
lower in the etanercept-treated groups than in the PBS-treated groups. Immunohistochemical staining using
rabbit anti-Iba1 antibody showed that the amount of microglia at the optic nerve head was noticeably lower
in the etanercept-treated groups than in the PBS-treated groups.
Conclusions: Etanercept significantly suppressed optic nerve injury in this rat model of acute ischemia. This in vivo
study suggests that etanercept might be a novel neuroprotective treatment agent for TNF-α–related disease.
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Background
Ischemia is considered to be a major pathogenic condi-
tion underlying several eye diseases including diabetic
retinopathy, retinal arterial/vein occlusion, and glaucoma
[1, 2]. Ischemia leads to apoptotic cell death through ac-
tivation of glial cells, increasing the production of cer-
tain neurotoxic mediators [3, 4].
Tumor necrosis factor-α (TNF-α), an inflammatory
cytokine, is one such factor that increases after ischemic
injury; it is also secreted in response to inflammation, in-
fection, and trauma [5]. TNF-α induces apoptotic neur-
onal damage through various signaling events within
cells after binding to its receptor [6]. Previous studies
have shown increased TNF-α production in in vitro and
in vivo ischemia models [3, 7, 8] and have demonstrated
that neutralization of TNF-α by intravitreal TNF-α anti-
body injection significantly preserves retinal function [8].
Etanercept (Enbrel®) is a TNF-α inhibitor that functions
as a decoy receptor that binds to TNF-α. It was the first
fusional monoclonal antibody against TNF-α to be mar-
keted for clinical use and is now commercially available.
Etanercept reduces the inflammatory effect of TNF-α
and is used clinically to treat several autoimmune dis-
eases such as rheumatoid arthritis, ankylosing spondyl-
itis, and psoriatic arthritis [9, 10]. Additionally, a recent
study showed that systemically injected etanercept ef-
fectively prevented retinal ganglion cell loss in a rat
model of glaucoma in which TNF-α and its receptor
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were detected at high levels, as well as in rats with
endotoxin-induced uveitis [11].
In the present study, we administered etanercept, a
widely used TNF-α inhibitor, subcutaneously after acute
ischemic injury to ascertain its effectiveness in prevent-
ing axonal ischemic damage. The aim of this study was
to determine whether etanercept reduces optic nerve de-
generation and decreases microglia activation in a rat
model of high-pressure-induced acute retinal ischemia.
Methods
Animal and retinal ischemia
Thirty-six male Sprague–Dawley rats weighing 250 to
300 g were used in this study. All animals were housed
in a standard animal facility with ad libitum access to
food and water in a room with a 12-h light–dark cycle
at constant temperature of 21 °C. All experimental
procedures conformed to the Association for Research
in Vision and Ophthalmology Statement for the Use of
Animals in Ophthalmic and Vision Research. The ani-
mal protocols were approved by the Institutional Ani-
mal Care and Use Committee of Yonsei University
Medical Center.
Before induction of ischemia, the rats were placed under
anesthesia by an intraperitoneal injection of 30 mg/kg of
tiletamine + zolazepam (Zoletil; Virbac, Fort Worth, TX)
and 10 mg/kg of xylazine (Rompun 2 %; Bayer, Peoria, IL).
Ischemia was induced by increasing the intraocular pres-
sure (IOP), thus blocking the blood supply from the ret-
inal artery to the retina. The anterior chamber of the right
eye was cannulated with a 30-gauge needle attached to si-
lastic tubing and a manometer to allow for infusion of
sterile 0.9 % saline solution. The IOP was increased by
raising the saline container to exceed the systemic arterial
blood pressure. An IOP of 130 mmHg was maintained for
60 min [8]. Whitening of the iris and loss of the red reflex
of the retina confirmed retinal ischemia. The IOP was
monitored every 5 min, and the absence of retinal perfu-
sion was maintained. The infusion was then stopped to
allow for reperfusion of the retinal vasculature, which was
confirmed by reappearance of the red reflex. The contra-
lateral left eye was treated by insertion of a 30-gauge nee-
dle into the anterior chamber through the cornea without
infusion, thus serving as a nonischemic control. The ani-
mals were humanely killed at various time points, and
their eyes were enucleated for morphologic and immuno-
histochemical studies.
Treatment with etanercept
We reconstituted etanercept (Enbrel®; Amgen, Thousand
Oaks, CA) with sterile water to 0.3 or 1.0 mg/kg. The rats
were distributed into three groups. Starting 1 day after in-
duction of acute ischemia or sham injection, the first and
second groups underwent subcutaneous injections of
etanercept at 0.3 mg/kg (n = 6) and 1.0 mg/kg (n = 15), re-
spectively, in the scalp three times per week until the day
of sacrifice. The second group was treated with 1.0 mg/
kg etanercept, and three animals were killed after
3 days, six after 2 weeks, and six after 4 weeks. The
third group (n = 15) was treated in the same manner with
the same volume of phosphate-buffered saline (PBS); three
animals were killed after 3 days, six after 2 weeks, and six
after 4 weeks. These doses were selected based upon pre-
vious studies that demonstrated the effectiveness of the
drug in other disease models [11].
Histological evaluation and immunohistochemistry
Initially, the eyeball was enucleated under anesthesia. To
minimize stretching damage during the enucleation pro-
cedure, the orbital part of the optic nerve was dissected
through a lateral conjunctival incision with a lateral
canthotomy. When the perineurium was visualized enough
to obtain an appropriate nerve length for the embedding
procedure, the optic nerve was cut approximately 3 mm
from the stump and removed from the eyeball. The
acquired axons were fixed in Karnovsky’s solution and
osmicated with 1 % osmium tetroxide, then processed for
routine paraffin embedding. The globes were sagittally em-
bedded, and 10-μm serial sections were cut in all cases.
The short piece of the proximal optic nerve was taken for
histology and fixed by immersion in 2.5 % glutaraldehyde
with 4 % paraformaldehyde in 0.1 M phosphate buffer
(pH 7.4) for 24 h at 4 °C. It was then placed in 1 % osmium
tetroxide in saline overnight and washed with cacodylate
buffer at room temperature. The tissue was subsequently
dehydrated in a graded alcohol series and embedded in
epoxy resin (Ladd Research Industries, Burlington, VT).
Semithin (<1.0-μm) cross sections of the optic nerve (ob-
tained from the midpoint of the sample, approximately
1.5 mm from the stump) were stained with 1 % toluidine
blue in 1 % sodium borate to measure the cross-sectional
area. Ultrathin (60-nm) cross sections were prepared for
transmission electron microscopy (TEM) (EM410; Philips,
Eindhoven, Netherlands).
The optic nerve, which was obtained 3 days after induc-
tion of ischemic injury, was used for immunohistochemi-
cal assessment of microglial activity. Retinal sections
(10 mm) with the optic nerve attached were preblocked
(PBS containing 10 % goat serum, 0.5 % gelatin, 3 % BSA,
and 0.2 % Tween-20) and then incubated with rabbit
anti-Iba1 antibody (1:500; Wako Chemicals USA Inc.,
Richmond, VA) as a microglial marker.
Quantification of optic nerve axon loss
The present study was based on the premise that the
cross sections of optic nerve axons are circular or oval
in shape and pertinent in size. Degenerated axons must
lose their circularity and deviate from the normal size
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range. Axonal degeneration is characterized by swollen
axons and splitting of the myelin sheath into layers
(hyperdense axons) with myelin sheath disruption and
extensive fibrosis in cases of severe damage.
Our methodology for quantifying the damage to the
optic nerve axon is described in detail elsewhere [12].
Briefly, 10 standard rectangular regions were randomly se-
lected from each section and photographed at 3000× mag-
nification. Nonaxonal regions were edited from each
photograph using ImageJ (developed by Wayne Rasband,
National Institutes of Health, Bethesda, MD; available
at http://rsb.info.nih.gov/ij/index.html) and Windows
Paint (Windows 7; Microsoft, Redmond, WA). Averages
were calculated by counting the number and averaged
areas of axoplasm (size of each axon internal to its myelin
sheath [13]) using the particle analysis plug-in within the
ImageJ software [14]. We assessed the axon damage with
the above averaged number and area of axoplasm, and the
sum of the calculated area was used to estimate the actual
area by comparing the proportion and size of each TEM
slide (1200 μm2).
Western blot analysis
Three days after induction of acute ischemic injury, the
microglial cell markers Iba1 (1:250; Abcam) and CD68
(1:100; Santa Cruz) were subjected to western blot ana-
lysis. Equal amounts of protein were electrophoresed in
10 % SDS-polyacrylamide gels. Separated proteins were
then electrotransferred to PVDF membranes (0.45 μm;
Millipore, Bedford, MA). After blocking with 5 % skim
milk, the membranes were incubated overnight with a pri-
mary antibody against Iba1 and CD68. The blotted mem-
branes were then incubated for 1 h at room temperature
with an HRP-conjugated secondary antibody directed
against rabbit IgG (1:2,000; Cell Signaling). Immunoreac-
tive bands were visualized by enhanced chemilumines-
cence and exposed onto X-ray film (AGFA, Belgium).
Statistical analysis
Results are expressed as means ± standard error of the
mean. Statistical analysis was performed nonparametri-
cally using the Mann–Whitney U-test (SPSS Statistics
19.0; Chicago, IL). A p-value of <0.05 was considered to
indicate statistical significance.
Results
Etanercept reduced pathologic changes in axons
We compared the axon morphology and density in cross
sections of the optic nerve under TEM. Four weeks after
induction of acute ischemia, the optic nerve showed
markedly greater axonal disorder than did that of sham-
treated controls; this disorder was characterized by axonal
swelling with separation of the myelin sheath, increased
variability in axonal size and shape, and decreased axonal
density (Fig. 1a and b). However, the axons in eyes treated
with 1.0 mg/kg of etanercept for 4 weeks maintained a
more normal configuration and a density similar to that of
the control axons (Fig. 1c).
The ratio of preserved axons was 0.88 ± 0.16 and 0.68 ±
0.17 in the 2-week 1.0 mg/kg etanercept-treated group
and PBS-treated group, respectively, with a marginally
significant difference (p = 0.062) (Table 1). The ratio of
preserved axons was 0.98 ± 0.04 and 0.65 ± 0.11 in the 4-
week 1.0-mg/kg etanercept-treated group and PBS-treated
group, respectively, with a statistically significant differ-
ence (p = 0.003). The 4-week 0.3 mg/kg etanercept-treated
group also demonstrated significantly greater axonal con-
servation than did the PBS-treated group (p = 0.021).
Etanercept decreased microglial activation
Immunohistochemical staining using a rabbit anti-Iba1
antibody showed that the amount of microglia at the
optic nerve head was noticeably lower in the 1.0 mg/kg
etanercept-treated group than in the PBS-treated group
on the third day after induction of acute ischemia (Fig. 2).
The western blot Iba1 and CD68 expression results are
Fig. 1 Etanercept prevents axonal damage secondary to ischemic injury. a-c Transmission electron micrographs of cross sections through rat
optic nerves. a Normal compact axons with myelination and round shape in sham-treated control optic nerves (black arrowhead). b Axonal
shrinkage with distortion of round shape and demyelination 4 weeks after acute ischemic injury. Separation of myelin sheath (white arrowhead)
and a whorl-shaped mass (white arrow). c Relatively preserved round axons with myelination in ischemic model treated with 1.0 mg/kg etanercept.
Original magnification: ×400; Scale bar, 10 μm
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shown in Fig. 3. In the control eyes without ischemic in-
jury, few Iba1- and CD68-positive cells were present in
the optic nerve. In the eyes with ischemia, on the other
hand, distinct protein bands corresponding to Iba1 and
CD68 were found with molecular weights of 17 kDa and
75–110 kDa, respectively. However, expression levels of
both markers were markedly lower in the 1.0 mg/kg
etanercept-treated eyes than in the control eyes. There-
fore, treatment with etanercept appeared to have pre-
vented the dramatic increase in Iba1 and CD68 expression
following ischemic insult.
Discussion
Etanercept is a commercially available TNF-α inhibitor,
and the present study confirmed its efficacy in terms of
preserving axonal structure and decreasing microglial
activation in a rat model of retinal ischemia. Previous
studies demonstrated that etanercept decreased intra-
ocular inflammation in a rat model of uveitis and pre-
vented retinal ganglion cell loss in a rat model of
glaucoma by reducing the TNF-α level [11, 15]. To our
knowledge, this is the first study to show the protective
effect of etanercept against acute retinal ischemia in an
in vivo model.
TNF-α plays an important role in ischemic neuronal
damage, and elevated levels of TNF-α have been docu-
mented in several previous studies [3, 7, 8, 11]. Therefore,
etanercept might also be effective for the prevention of
axonal ischemic damage after acute ischemic injury. Actu-
ally, Berger et al [8]. demonstrated that intravitreal TNF-α
antibody administration prevented ischemic retinal injury
in a rat model. However, that study had drawbacks in that
intravitreal injection could induce additional inflammation
and increase the IOP. To overcome such limitations and
assess the effect of lowering TNF-α, we used subcutane-
ous injections of etanercept. As a result, we confirmed
that etanercept effectively prevents axonal ischemic dam-
age after systemic administration.
Previous studies have also shown that microglia are
the source of TNF-α and that the activation of these
cells may quantitatively reflect the severity of optic nerve
damage [3, 11, 16, 17]. Ischemic injury may break down
the blood–retina barrier or cause local stress at the optic
nerve head, subsequently eliciting a glial response. When
microglia are activated, they rapidly transform by increas-
ing the size of their cell body, thickening their processes,
and decreasing the ramification of their distal branches
until they become almost completely round. Functionally,
activated microglia may continuously present antigens
and generate several cytokines such as TNF-α, which plays
an important role in the inflammatory response [18]. This
microglial activation occurs along the entire optic pathway
and seems to be closely correlated with axonal damage.
Therefore, microglial activation could be a useful quantita-
tive tool with which to assess the status of optic nerve
damage in models of optic nerve injury.
In the present study, we confirmed the occurrence of
microglial activation using microglial markers on the third
day after induction of acute ischemia. Roh et al [11]. re-
ported that the degree of elevation of the TNF-α level
within 3 days after IOP elevation in a rat model of glau-
coma was correlated with microglial activation by 7 days.
Therefore, we evaluated microglial activation 3 days after
ischemic injury to elucidate the microglial-induced inflam-
matory reaction. Two microglial markers, Iba1 and CD68,
were used in this study. Iba1 labels both quiescent and ac-
tivated microglia and provided an index of microglial
density, whereas lysosomal antigen CD68 served as a
measure of microglial phagocytic activity [19].
We used a semi-automated counting method by TEM
in which we calculated the ratio of preserved axons to
Table 1 Comparison of the ratio of preserved axons in the
etanercept and control groups
Etanercept treatment group PBS treatment group p-value
1.0 mg/kg for 2 weeks 0.88 ± 0.16 0.68 ± 0.17 0.062
1.0 mg/kg for 4 weeks 0.98 ± 0.04 0.65 ± 0.11 0.003
0.3 mg/kg for 4 weeks 0.78 ± 0.40 0.65 ± 0.08 0.021
PBS phosphate-buffered saline
Fig. 2 Immunohistochemical staining 3 days after acute ischemic injury. Using a rabbit anti-Iba1 antibody, immunohistochemical staining showed
that the number of microglia (arrow) at the optic nerve head was noticeably lower in the 1.0 mg/kg etanercept-treated group (a) than in the
PBS-treated group (b). Original magnification: ×20 (A, B); Scale bar, 1000 μm. PBS, phosphate-buffered saline
Bae et al. BMC Ophthalmology  (2016) 16:75 Page 4 of 6
assess the axonal damage [20]. Marina et al [14]. described
a semi-automated targeted sampling method using light
micrographs, and we applied this technique to our TEM
slides. By minimizing the proportion of subjective proce-
dures and using TEM photographs, we quantitatively eval-
uated the status of the axons with less labor and avoided
the possibility of underestimation, which might occur
using light microscopy. Using this method, we found
that the number and configuration of axons after acute
ischemic injury were significantly more preserved in
the etanercept-treated group than in the PBS-treated
group.
This study had several limitations. First, we did not dir-
ectly evaluate retinal ganglion cell loss or the TNF-α level.
However, retinal ganglion cell loss after ischemia has been
described in many previous studies, and the TNF-α–low-
ering effect of etanercept is also apparent. This study
aimed to demonstrate the actual effects of commercialized
etanercept on acute ischemic injury. Therefore, after in-
duction of acute ischemia, we determined whether etaner-
cept suppresses microglial activity and thus lowers the
TNF-α level, helping to preserve the axons of the optic
nerve. Second, axonal damage might be induced by both
mechanical and ischemic damage. A very high IOP was re-
quired to achieve an ischemic condition. During this
process, the optic nerve head might have sustained mech-
anical damage caused by the elevated pressure. Therefore,
we cannot conclusively assert that the axons were dam-
aged only by the ischemic condition. Finally, we could not
determine the optimal dose and duration of etanercept.
Although the effect of etanercept showed a tendency to
increase with the dosage and duration, further studies to
investigate the clinical use of etanercept are warranted.
Even considering these limitations, this study has
strength of the first study which showed the protective
effect of commercialized etanercept against acute ret-
inal ischemia in an in vivo model.
Conclusions
Etanercept, a commercially available TNF-α inhibitor,
showed a significant protective effect against axonal
damage after induction of acute ischemia in in vivo rat
models. Additional studies on the neuroprotective ef-
fect of etanercept will help to establish whether this
agent is a good candidate for novel treatment of various
neuronal diseases.
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